FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Keyue Ding

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Canada

Physiology

Mutation

Co-author Network

Publications

TOP 3
Maisa Yoshimoto; Neil E Fleshner; Keyue Ding; Anthony M Joshua; Olga Ludkovski; Kyu S Song; Jeremy A Squire; Joan M Sweet; Greg Trottier; Andrew J Evans
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Ming Tsao; Akira Sakurada; Keyue Ding; Sarit Aviel-Ronen; Olga Ludkovski; Ni Liu; Aurélie Le Maître; David R Gandara; David H Johnson; James Rigas; Lesley Seymour; Frances A Shepherd
Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Daniel S Sutton; Weidong Kong; Keyue Ding; William J Mackillop
The use of palliative radiotherapy for bone metastasis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Keyue Ding (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Maisa Yoshimoto; Neil E Fleshner; Keyue Ding; Anthony M Joshua; Olga Ludkovski; Kyu S Song; Jeremy A Squire; Joan M Sweet; Greg Trottier; Andrew J Evans
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2013;26(3):435-47.
2011: Ming Tsao; Akira Sakurada; Keyue Ding; Sarit Aviel-Ronen; Olga Ludkovski; Ni Liu; Aurélie Le Maître; David R Gandara; David H Johnson; James Rigas; Lesley Seymour; Frances A Shepherd
Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(1):139-47.
2010: Daniel S Sutton; Weidong Kong; Keyue Ding; William J Mackillop
The use of palliative radiotherapy for bone metastasis.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010;97(3):548-53.
2010: R Goodwin; Keyue Ding; Lesley Seymour; A LeMaître; Andrew Arnold; Frances A Shepherd; M Dediu; T Ciuleanu; D Fenton; M Zukin; D Walde; F Laberge; M Vincent; P M Ellis; S A Laurie
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(11):2220-6.
2010: Chang-Qi Zhu; Keyue Ding; Dan Strumpf; Barbara A Weir; Matthew Meyerson; Nathan Pennell; Roman K Thomas; Katsuhiko Naoki; Christine Ladd-Acosta; Ni Liu; Melania Pintilie; Sandy D Der; Lesley Seymour; Igor Jurisica; Frances A Shepherd; Ming-Sound Tsao
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(29):4417-24.
2010: Charles Butts; Keyue Ding; Lesley Seymour; Philip Twumasi-Ankrah; Barbara Graham; David R Gandara; David H Johnson; Kenneth A Kesler; Mark Green; mark vincent; Yvon Cormier; Glenwood Goss; Brian Findlay; Michael Johnston; Ming-Sound Tsao; Frances A Shepherd
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(1):29-34.
2009: Raymond W Jang; Aurélie Le Maître; Keyue Ding; Timothy Winton; Andrea Bezjak; Lesley Seymour; Frances A Shepherd; Natasha B Leighl
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4268-73.
2009: Christopher M Booth; Aurélie Le Maître; Keyue Ding; Kristen Farn; Michael Fralick; Cameron Phillips; David W Cescon; Ralph M Meyer
Presentation of nonfinal results of randomized controlled trials at major oncology meetings.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(24):3938-44.
2008: Andrea Bezjak; Christopher W Lee; Keyue Ding; Michael D Brundage; Timothy Winton; Barbara Graham; Marlo Whitehead; David H Johnson; Robert B Livingston; Lesley Seymour; Frances A Shepherd
Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5052-9.
2008: Chang-Qi Zhu; Gilda da Cunha Santos; Keyue Ding; Akira Sakurada; Jean-Claude Cutz; Ni Liu; Tong Zhang; Paula Marrano; Marlo Whitehead; Jeremy A Squire; Suzanne Kamel-Reid; Lesley Seymour; Frances A Shepherd; Ming-Sound Tsao
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(26):4268-75.
2008: Timothy R Asmis; Keyue Ding; Lesley Seymour; Frances A Shepherd; Natasha B Leighl; Timothy Winton; Marlo Whitehead; Johanna N Spaans; Barbara C Graham; Glenwood D Goss
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):54-9.
2007: Ming Tsao; Sarit Aviel-Ronen; Keyue Ding; Davina Lau; Ni Liu; Akira Sakurada; Marlo Whitehead; Chang-Qi Zhu; Robert Livingston; David H Johnson; James Rigas; Lesley Seymour; Timothy Winton; Frances A Shepherd
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5240-7.
2007: D A Macdonald; Keyue Ding; Mary K Gospodarowicz; W A Wells; Robert G Pearcey; Joseph Michael Connors; Jane N Winter; Sandra J Horning; Marina Djurfeldt; Lois E Shepherd; Ralph M Meyer
Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(10):1680-4.
2007: Andrew M Arnold; Lesley Seymour; Michael Smylie; Keyue Ding; Yee C Ung; Brian Findlay; Christopher W Lee; Marina Djurfeldt; Marlo Whitehead; Peter Ellis; Glenwood Goss; Adrien Chan; Jacinta Meharchand; Yasmin Alam; Richard Gregg; Charles Butts; Peter Langmuir; Frances A Shepherd
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4278-84.
2007: Raymond Ng; Baktiar Hasan; Nicole Mittmann; Marie Florescu; Frances A Shepherd; Keyue Ding; Charles Butts; Yvon Cormier; Gail Darling; Glenwood Goss; Richard Inculet; Lesley Seymour; Timothy Winton; William K Evans; Natasha B Leighl
Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2256-61.
2007: Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):1960-6.
2007: Carmela Pepe; Baktiar Hasan; Timothy Winton; Lesley Seymour; Barbara Graham; Robert B Livingston; David H Johnson; James R Rigas; Keyue Ding; Frances A Shepherd
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(12):1553-61.
2007: I Gauthier; Keyue Ding; Timothy Winton; Frances A Shepherd; Robert Livingston; David H Johnson; James Rigas; Marlo Whitehead; Barbara Graham; Lesley Seymour
Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.
Lung cancer (Amsterdam, Netherlands) 2007;55(3):357-63.
2007: Pascal Sève; Raymond Lai; Keyue Ding; Timothy Winton; Charles Butts; John Mackey; Charles Dumontet; Laith Dabbagh; Sarit Aviel-Ronen; Lesley Seymour; Marlo Whitehead; Ming Tsao; Frances A Shepherd; Tony Reiman
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(3):994-9.
2007: Chaim Shustik; Andrew R Belch; Sue Robinson; Sheldon H Rubin; Sean P Dolan; Michael J Kovacs; Kuljit S Grewal; David Walde; Robert Barr; Jonathan Wilson; Kulwant Gill; Linda Vickars; Leona Rudinskas; Dolores A Sicheri; Kenneth Wilson; Marina Djurfeldt; Lois E Shepherd; Keyue Ding; Ralph M Meyer
A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.
British journal of haematology 2007;136(2):203-11.
2006: Rebecca K S Wong; Nancy Paul; Keyue Ding; Marlo Whitehead; Michael D Brundage; Anthony Fyles; Derek Wilke; Abdenour Nabid; André Fortin; Don Wilson; Michael McKenzie; Ida Ackerman; Luis Souhami; Pierre Chabot; Joseph L Pater
5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(21):3458-64.
2005: Ralph M Meyer; Mary K Gospodarowicz; Joseph Michael Connors; Robert G Pearcey; Andrea Bezjak; Woodrow A Wells; Bruce F Burns; Jane N Winter; Sandra J Horning; A Rashid Dar; Marina Djurfeldt; Keyue Ding; Lois E Shepherd
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4634-42.
2005: Ming Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
The New England journal of medicine 2005;353(2):133-44.
2005: Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming Tsao; David R Gandara; Kenneth Kesler; Todd L Demmy; Frances A Shepherd
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
The New England journal of medicine 2005;352(25):2589-97.
2005: Naveed Alam; Frances A Shepherd; Timothy Winton; Barbara Graham; David Johnson; Robert Livingston; James Rigas; Marlo Whitehead; Keyue Ding; Lesley Seymour
Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
Lung cancer (Amsterdam, Netherlands) 2005;47(3):385-94.
2004: A Keith Stewart; Christine I Chen; Kang Howson-Jan; Darrell White; Jean Roy; Michael J Kovacs; Chaim Shustik; Anna Sadura; Lois Shepherd; Keyue Ding; Ralph M Meyer; Andrew R Belch
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8170-6.
2004: Michael Crump; Tara Baetz; Stephen Couban; Andrew R Belch; Deborah Marcellus; Kang Howson-Jan; Kevin Imrie; Robert Myers; Grenfell Adams; Keyue Ding; Nancy Paul; Lois Shepherd; Jose Iglesias; Ralph Meyer
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Cancer 2004;101(8):1835-42.
2003: T Baetz; Andrew R Belch; Stephen Couban; Kevin Imrie; J Yau; R Myers; Keyue Ding; N Paul; L Shepherd; J Iglesias; R Meyer; Michael Crump
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1762-7.